1044256-89-4Relevant articles and documents
Novel biphenyl derivative as well as preparation method and medical application thereof
-
Paragraph 0046; 0065; 0108-0110; 0228-0230, (2021/07/21)
The invention relates to the field of medicinal chemistry, and discloses biphenyl derivatives with PD-1/PD-L1 inhibitory activity as well as a preparation method and application of the biphenyl derivatives. The invention further discloses a composition containing the biphenyl derivative with the PD-1/PD-L1 inhibitory activity or the pharmaceutically acceptable salt of the biphenyl derivative and a pharmaceutically acceptable carrier of the biphenyl derivative, and application of the biphenyl derivative in preparation of a PD-1/PD-L1 inhibitor. The compound can be used for treating tumors.
Novel phenanthrene compounds, a method of making the same and organic electronic devices using the same
-
Paragraph 0236-0239, (2019/10/22)
The present invention relates to novel phenanthrene compounds having excellent luminous efficiency and lifespan, a manufacturing method thereof, and an organic electronic device including the novel phenanthrene compounds. The novel phenanthrene compounds according to the present invention can form steric conformation, can improve performance through improvement of electronic density, also can improve performance by regulating the molecular weight and position of a functional group because the molecular weight of the compounds is low, and can minutely regulate luminous wavelength and improve performance according to types of the functional groups. As the result, the organic electronic device including the novel phenanthrene compounds has high brightness, excellent thermal resistance, long lifespan, and high efficiency.
ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS
-
, (2008/12/07)
The invention provides well-defined aryl fluoroethyl ureas that are useful as selective alpha2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of alpha2 adrenergic receptors.